Skip to main content

You are here:

Phase 3, Open-label Study Evaluating the Long-term Safety of VX445 Combination Therapy in Subjects with Cystic Fibrosis

This study is being done to learn more about the safety and tolerability of the combination of elexacaftor (VX-445), TEZ and IVA in patients with CF.

Key Eligibility Criteria

Diagnosis of Cystic Fibrosis, Age 18years +

Therapeutic Area
Cystic Fibrosis
Type of Study
Clinical Trial VX18-445-113
Study Status
Vertex Pharmaceuticals
Principal Investigator
Prof Edward McKone